4D Molecular Therapeutics announced on November 17 2025 that Kristian Humer will serve as its new Chief Financial Officer, effective immediately. Humer brings more than twenty years of experience in corporate finance and strategic operations, having held senior roles as Managing Director in Citi’s Healthcare Investment Banking Group and as CFO of publicly traded biopharma companies Foghorn Therapeutics and Viridian Therapeutics.
Humer’s background in financing and scaling biopharma operations aligns closely with 4D’s current priorities. The company is advancing its lead gene‑therapy candidate, 4D‑150, through Phase 3 trials for wet age‑related macular degeneration and diabetic macular edema, and it is preparing for eventual commercialization. A CFO with deep experience in capital markets and corporate development is positioned to guide the company through the capital‑intensive late‑stage development and the transition to a commercial entity.
Financially, 4D maintains a robust liquidity profile, with a current ratio of 8.42 and a cash runway that extends through 2028 thanks to recent equity offerings and a partnership with Otsuka Pharmaceutical. While the company’s revenue remains modest—$0.12 million—and its operating and net margins are negative, the strong cash position provides the flexibility needed to fund ongoing clinical work and future growth initiatives.
CEO David Kirn said the appointment “strengthens our financial leadership and positions 4D to manage the capital demands of our accelerated clinical timelines and future growth opportunities.” He added that Humer’s expertise will help the company maintain financial discipline while pursuing strategic investments and commercial readiness.
Humer will oversee financial strategy, capital allocation, corporate development, and support for commercial readiness initiatives. His role is critical to ensuring that 4D can secure the necessary funding for late‑stage trials, navigate regulatory milestones, and build the infrastructure required for a successful market launch. By aligning financial planning with the company’s clinical roadmap, the new CFO will help translate scientific progress into sustainable business growth.
The appointment signals 4D’s commitment to disciplined financial management as it moves from a research‑focused organization to a commercial‑ready biopharma company. With a seasoned CFO in place, the company is better positioned to manage the substantial capital requirements of Phase 3 trials, secure additional financing, and ultimately bring its gene‑therapy products to patients and shareholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.